Looking for a rally post interest rate announcement.
Tuesday, December 15, 2015
Medical Stocks Technical Watchlist - December 2015
Here's my final watchlist for 2015.
Looking for a rally post interest rate announcement.
Looking for a rally post interest rate announcement.
Wednesday, December 2, 2015
A tough 2015 for Marketocracy's Fund Managers
2015 has been a difficult investment year for Marketocracy's Masters & Top Fund Managers according to performance data just released.
On average Marketocracy Managers under-performed the S&P500 index. Year to date, they returned -3.66% vs 1.04% for the S&P500.
27% of Managers (6/22) beat the return of the S&P500.
The best Marketocracy performers (ytd):
#1 Justin Uyehara with 19.86% (@ a 10yr annual return of 20.9%)
#2 Wayne Himelsein with 19.60% (@ a 10yr annual return of 13.1%)
#3 Bruce Pile with 5.32% (@ a 10yr annual return of -4.0%)
Below is a detailed look at all the Managers performances:
My Fund:
My Medicals focused fund is down 3.56% ytd (@ a 10-year annual return of 15.2%). It has dropped in ranking from #1 to #14 during the past 4 months.
My Fund's performance suffered heavily during the recent biotech sector sell-off. I primarily hold small-cap positions these unfortunately were the worst affected during the sector sell-off.
My Fund along with the Biotech sector are now showing signs of a recovery which is encouraging. I remain optimistic for the long-term about investing in this space despite the recent turmoil and warnings we are in a "biotech bubble". I believe this sector has more prosperous years ahead of it. Our biggest near-term risk is a possible Reserve Bank interest rate raise later this month.
I feel my Fund is positioned for a strong finish to 2015. December holds several catalysts that could significantly boost my Fund's performance;
My largest holding, Northwest Biotherapeutics (NWBO) is due to make an announcement clarifying the state of its Phase 3 trial. And my 3rd largest holding, TG Therapeutics (TGTX) is presenting at ASH this week, they will present trial data with 4 abstracts.
Disclosure - Marketocracy Funds are available for investment through SMAs. Here is a link to my fund http://www.marketocracy.com/managers.php?manager=781
I do not short stocks.
On average Marketocracy Managers under-performed the S&P500 index. Year to date, they returned -3.66% vs 1.04% for the S&P500.
27% of Managers (6/22) beat the return of the S&P500.
The best Marketocracy performers (ytd):
#1 Justin Uyehara with 19.86% (@ a 10yr annual return of 20.9%)
#2 Wayne Himelsein with 19.60% (@ a 10yr annual return of 13.1%)
#3 Bruce Pile with 5.32% (@ a 10yr annual return of -4.0%)
Below is a detailed look at all the Managers performances:
My Fund:
My Medicals focused fund is down 3.56% ytd (@ a 10-year annual return of 15.2%). It has dropped in ranking from #1 to #14 during the past 4 months.
My Fund's performance suffered heavily during the recent biotech sector sell-off. I primarily hold small-cap positions these unfortunately were the worst affected during the sector sell-off.
My Fund along with the Biotech sector are now showing signs of a recovery which is encouraging. I remain optimistic for the long-term about investing in this space despite the recent turmoil and warnings we are in a "biotech bubble". I believe this sector has more prosperous years ahead of it. Our biggest near-term risk is a possible Reserve Bank interest rate raise later this month.
I feel my Fund is positioned for a strong finish to 2015. December holds several catalysts that could significantly boost my Fund's performance;
My largest holding, Northwest Biotherapeutics (NWBO) is due to make an announcement clarifying the state of its Phase 3 trial. And my 3rd largest holding, TG Therapeutics (TGTX) is presenting at ASH this week, they will present trial data with 4 abstracts.
Disclosure - Marketocracy Funds are available for investment through SMAs. Here is a link to my fund http://www.marketocracy.com/managers.php?manager=781
I do not short stocks.
Subscribe to:
Posts (Atom)